<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04539938</url>
  </required_header>
  <id_info>
    <org_study_id>SGNTUC-025</org_study_id>
    <nct_id>NCT04539938</nct_id>
  </id_info>
  <brief_title>A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer</brief_title>
  <acronym>HER2CLIMB-04</acronym>
  <official_title>A Single Arm, Open Label Phase 2 Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seagen Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seagen Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial studies how well the drug tucatinib works when given with trastuzumab deruxtecan.&#xD;
      It will also look at what side effects happen when these drugs are given together. A side&#xD;
      effect is anything a drug does besides treating cancer.&#xD;
&#xD;
      Participants in this trial have HER2-positive (HER2+) breast cancer that has either spread to&#xD;
      other parts of the body (metastatic) or cannot be removed completely with surgery&#xD;
      (unresectable). All participants will get both tucatinib and trastuzumab deruxtecan.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2020</start_date>
  <completion_date type="Anticipated">October 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">October 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confirmed objective response rate (cORR) per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 according to investigator assessment</measure>
    <time_frame>From start of treatment up to approximately 3 years</time_frame>
    <description>ORR is defined as the proportion of subjects with confirmed complete response (CR) or partial response (PR) per RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) per RECIST v1.1 according to investigator assessment</measure>
    <time_frame>From start of treatment up to approximately 3 years</time_frame>
    <description>DOR is defined as the time from first documentation of objective response to the first documentation of disease progression per RECIST v1.1 or death from any cause, whichever occurs earlier</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) per RECIST v1.1 according to investigator assessment</measure>
    <time_frame>From start of treatment up to approximately 3 years</time_frame>
    <description>PFS is defined as the time from start of study treatment to first documentation of tumor progression or to death due to any cause, whichever comes first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR) per RECIST v1.1 according to investigator assessment</measure>
    <time_frame>From start of treatment up to approximately 3 years</time_frame>
    <description>DCR is defined as the proportion of subjects with confirmed CR, PR or stable disease according to RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From start of treatment up to approximately 5 years</time_frame>
    <description>OS is defined as the time from treatment initiation to death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>From start of treatment up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of laboratory abnormalities</measure>
    <time_frame>From start of treatment up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of dose modifications</measure>
    <time_frame>From start of treatment up to approximately 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of treatment discontinuations</measure>
    <time_frame>From start of treatment up to approximately 3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Single Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tucatinib + trastuzumab deruxtecan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tucatinib</intervention_name>
    <description>300 mg orally twice daily</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>TUKYSA, ARRY-380, ONT-380</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>trastuzumab deruxtecan</intervention_name>
    <description>5.4 mg/kg via intravenous (into the vein; IV) infusion on Day 1 of each of 21-day cycle</description>
    <arm_group_label>Single Arm</arm_group_label>
    <other_name>Enhertu, DS-8201</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Have confirmed HER2+ breast cancer, as defined by the current American Society of&#xD;
             Clinical Oncology - College of American Pathologists (ASCO/CAP) guidelines, previously&#xD;
             determined at a Clinical Laboratory Improvements Amendments (CLIA)-certified or&#xD;
             International Organization for Standardization (ISO)-accredited laboratory.&#xD;
&#xD;
          -  Have received 2 or more prior anti-HER2-based regimens in the metastatic setting&#xD;
&#xD;
          -  Have progression of unresectable LA/M breast cancer after last systemic therapy (as&#xD;
             confirmed by investigator), or be intolerant of last systemic therapy&#xD;
&#xD;
          -  Have measurable disease assessable by RECIST v1.1&#xD;
&#xD;
          -  Have Eastern Cooperative Oncology Group Performance Status (ECOG PS) 0 or 1&#xD;
&#xD;
          -  Have a life expectancy of at least 6 months, in the opinion of the investigator&#xD;
&#xD;
          -  CNS Inclusion - Based on medical history and screening contrast brain magnetic&#xD;
             resonance imaging (MRI), participants with a history of brain metastases must have one&#xD;
             of the following:&#xD;
&#xD;
               -  Untreated brain metastases not needing immediate local therapy. For participants&#xD;
                  with untreated central nervous system (CNS) lesions &gt;2.0 cm on screening contrast&#xD;
                  brain MRI, discussion with and approval from the medical monitor is required&#xD;
                  prior to enrollment&#xD;
&#xD;
               -  Previously treated brain metastases&#xD;
&#xD;
                    -  Brain metastases previously treated with local therapy may either be stable&#xD;
                       since treatment or may have progressed since prior local CNS therapy,&#xD;
                       provided that there is no clinical indication for immediate re-treatment&#xD;
                       with local therapy in the opinion of the investigator&#xD;
&#xD;
                    -  Participants treated with CNS local therapy for newly identified or&#xD;
                       previously treated progressing lesions found on contrast brain MRI performed&#xD;
                       during screening for this study may be eligible to enroll if all of the&#xD;
                       following criteria are met:&#xD;
&#xD;
                         -  Time since whole brain radiation therapy (WBRT) is ≥14 days prior to&#xD;
                            first dose of study treatment, time since stereotactic radiosurgery&#xD;
                            (SRS) is ≥7 days prior to first dose of study treatment, or time since&#xD;
                            surgical resection is ≥28 days&#xD;
&#xD;
                         -  Other sites of measurable disease by RECIST v1.1 are present&#xD;
&#xD;
                    -  Relevant records of any CNS treatment must be available&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Have previously been treated with:&#xD;
&#xD;
               -  Lapatinib or neratinib within 12 months of starting study treatment (except in&#xD;
                  cases where lapatinib or neratinib was given for ≤21 days and was discontinued&#xD;
                  for reasons other than disease progression or severe toxicity)&#xD;
&#xD;
               -  Tucatinib or enrolled on a tucatinib clinical trial&#xD;
&#xD;
               -  Any investigational HER2/epidermal growth factor receptor (EGFR) or HER2 tyrosine&#xD;
                  kinase inhibitor (TKI) (eg, afatinib) at any time previously&#xD;
&#xD;
               -  Trastuzumab deruxtecan or another antibody-drug conjugate (ADC) consisting of an&#xD;
                  exatecan derivative&#xD;
&#xD;
          -  Have received treatment with:&#xD;
&#xD;
               -  Any systemic anti-cancer therapy (including hormonal therapy) or experimental&#xD;
                  agent ≤21 days of first dose of study treatment or are currently participating in&#xD;
                  another interventional clinical trial. An exception for the washout of hormonal&#xD;
                  therapies is gonadotropin releasing hormone (GnRH) agonists used for ovarian&#xD;
                  suppression in premenopausal women, which are permitted concomitant medications&#xD;
&#xD;
               -  Treatment with non-CNS radiation ≤7 days prior to first dose of study treatment&#xD;
&#xD;
               -  Major surgery &lt;28 days of first dose of study treatment&#xD;
&#xD;
          -  Have clinically significant cardiopulmonary disease (such as history of iterstitial&#xD;
             lung disease (ILD)/pneumonitis that required systemic corticosteroids, or have current&#xD;
             ILD/pneumonitis, or where suspected ILD /pneumonitis cannot be ruled out be imaging at&#xD;
             screening)&#xD;
&#xD;
          -  Have known myocardial infarction or unstable angina within 6 months prior to first&#xD;
             dose of study treatment&#xD;
&#xD;
          -  Known to be positive for hepatitis B by surface antigen expression. Known to be&#xD;
             positive for hepatitis C infection. Participants who have been treated for hepatitis C&#xD;
             infection are permitted if they have documented sustained virologic response of 12&#xD;
             weeks&#xD;
&#xD;
          -  Presence of known chronic liver disease&#xD;
&#xD;
          -  Known to be positive for human immunodeficiency virus (HIV)&#xD;
&#xD;
          -  Active or uncontrolled clinically serious infection&#xD;
&#xD;
          -  Are pregnant, breastfeeding, or planning a pregnancy&#xD;
&#xD;
          -  Have inability to swallow pills or significant gastrointestinal disease which would&#xD;
             preclude the adequate oral absorption of medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jorge Ramos, DO</last_name>
    <role>Study Director</role>
    <affiliation>Seagen Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seagen Trial Information Support</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35249</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nazma Chowdhury</last_name>
      <phone>205-934-4778</phone>
    </contact>
    <investigator>
      <last_name>Erica M Stringer-Reasor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Arizona Oncology Associates, PC - HOPE</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85704</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Vasquez</last_name>
      <phone>281-863-5639</phone>
      <email>Ana.Vasquez@McKesson.com</email>
    </contact>
    <investigator>
      <last_name>Rachel Swart</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope National Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010-3000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sayeh Lavasani</last_name>
      <phone>626-256-4673</phone>
      <email>slavasani@coh.org</email>
    </contact>
    <investigator>
      <last_name>Sayeh Lavasani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UCLA Department of Medicine - Hematology &amp; Oncology</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Rocha</last_name>
      <phone>310-998-4747 x16907</phone>
    </contact>
    <investigator>
      <last_name>Sara Hurvitz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of California at San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94134</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nathalie Kacik</last_name>
      <phone>415-885-7213</phone>
    </contact>
    <investigator>
      <last_name>Amy Jo Chien</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital / University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045-0510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leah Adams</last_name>
      <phone>720-848-7341</phone>
      <email>leah.adams@cuanschutz.edu</email>
    </contact>
    <investigator>
      <last_name>Virginia Borges</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Lombardi Cancer Center / Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Castle</last_name>
      <phone>202-444-2209</phone>
    </contact>
    <investigator>
      <last_name>Paula Pohlmann</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Asma Dilawari</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - North Region</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Katie Goodman</last_name>
    </contact>
    <investigator>
      <last_name>Gail L Wright</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Winship Cancer Institute / Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jane L Meisel</last_name>
      <phone>404-778-1900</phone>
    </contact>
    <investigator>
      <last_name>Jane L Meisel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Cancer Specialists / Northside Hospital Cancer Institute</name>
      <address>
        <city>Sandy Springs</city>
        <state>Georgia</state>
        <zip>30341</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anila Lokhandwala</last_name>
    </contact>
    <investigator>
      <last_name>Amelia B Zelnak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James Graham Brown Cancer Center / University of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>University of Lousiville James Graham Brown Cancer Center</last_name>
      <phone>502-562-4673</phone>
    </contact>
    <investigator>
      <last_name>Elizabeth Riley</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Dana Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ian Krop</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Piper Cancer Institute</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacquelyn J Underhill</last_name>
      <phone>612-863-3929</phone>
      <email>jacquelyn.underhill@allina.com</email>
    </contact>
    <investigator>
      <last_name>Michaela Tsai</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amy Krie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ciara O'Sullivan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Luke's Cancer Institute LLC</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Melissa Lising</last_name>
      <phone>816-932-2677</phone>
    </contact>
    <investigator>
      <last_name>Timothy J Pluard</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HCA Midwest Health Kansas City</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Nebraska Cancer Specialists</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <zip>68130</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan Meays</last_name>
      <phone>402-691-6972</phone>
      <email>mmeays@nebraskacancer.com</email>
    </contact>
    <investigator>
      <last_name>Margaret Block, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Aretha DiSalvo</last_name>
      <phone>551-996-8258</phone>
    </contact>
    <investigator>
      <last_name>Deena M Graham</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Shanu Modi</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wake Forest Baptist Medical Center / Wake Forest University</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angela Howell, RN. CCRP</last_name>
      <phone>336-713-3155</phone>
    </contact>
    <investigator>
      <last_name>Susan Melin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Lopez</last_name>
      <phone>503-215-5696</phone>
      <email>canrsrchstudies@providence.org</email>
    </contact>
    <investigator>
      <last_name>Alison K Conlin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C.</name>
      <address>
        <city>Tigard</city>
        <state>Oregon</state>
        <zip>97223</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jay C Andersen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Magee Womens Hospital of UPMC</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claire Berger</last_name>
      <phone>412-641-6373</phone>
    </contact>
    <investigator>
      <last_name>Adam Brufsky</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chattanooga Oncology and Hematology Associates/Tennessee Oncology-Memorial Plaza</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ask Sarah</last_name>
      <phone>844-482-4812</phone>
    </contact>
    <investigator>
      <last_name>Brooke R Daniel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology-Nashville/Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ask Sarah</last_name>
      <phone>844-482-4812</phone>
    </contact>
    <investigator>
      <last_name>Erika P Hamilton</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Presbyterian Cancer Center Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Vasquez</last_name>
      <phone>281-863-5639</phone>
      <email>Ana.Vasquez@McKesson.com</email>
    </contact>
    <investigator>
      <last_name>Kristi J McIntyre</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yolanda Pitts</last_name>
      <phone>214-648-6679</phone>
    </contact>
    <investigator>
      <last_name>Barbara Haley</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nisha Unni</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center / University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rashmi Murthy</last_name>
      <phone>713-745-4367</phone>
    </contact>
    <investigator>
      <last_name>Rashmi Murthy</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Specialists, PC</name>
      <address>
        <city>Fairfax</city>
        <state>Virginia</state>
        <zip>22031</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Vasquez</last_name>
      <phone>281-863-5639</phone>
      <email>Ana.Vasquez@McKesson.com</email>
    </contact>
    <investigator>
      <last_name>Neelima Denduluri</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne M Favret</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncology and Hematology Assoc of SW VA DBA Blue Ridge Cancer Care</name>
      <address>
        <city>Salem</city>
        <state>Virginia</state>
        <zip>24153</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Vasquez</last_name>
      <phone>281-863-5639</phone>
      <email>Ana.Vasquez@McKesson.com</email>
    </contact>
    <investigator>
      <last_name>Paul Richards</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance / University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109-1023</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaveta Vinayak</last_name>
      <phone>206-606-6329</phone>
    </contact>
    <investigator>
      <last_name>Jennifer M Specht</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shaveta Vinayak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Carbone Cancer Center / University of Wisconsin</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Elisavet Paplomata</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>August 31, 2020</study_first_submitted>
  <study_first_submitted_qc>August 31, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 7, 2020</study_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HER2+ breast cancer</keyword>
  <keyword>HER2-positive breast cancer</keyword>
  <keyword>Metastatic breast cancer</keyword>
  <keyword>Stage IV breast cancer</keyword>
  <keyword>Seattle Genetics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Tucatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

